Open Access

Interactive role of breast cancer on dyslipidemia and hypertension metabolic risk according to treatment exposure and menopausal status

Safaa A. Al-Zeidaneen
Safaa A. Al-Zeidaneen
, 
Mousa N. Ahmad
Mousa N. Ahmad
, 
Ali D. Al-Ebous
Ali D. Al-Ebous
 and 
Rawan MohD Al Saudi
Rawan MohD Al Saudi
   | May 02, 2021
Forum of Clinical Oncology's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Research Article
Published Online: May 02, 2021
Page range: 39 - 46
Received: Jun 30, 2018
Accepted: Apr 29, 2019
DOI: https://doi.org/10.2478/fco-2019-0018
Keywords
© 2021 Safaa A. Al-Zeidaneen et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Prevalence of dyslipidemia risk factors and hypertension in pre and postmenopause according to treatment exposure(1, 2, 3, 4, 5)

Metabolic risk Newly-diagnosed (N = 134) Recently-diagnosed (N = 262) Whole sample (N = 396)
Premeno-pause (N = 80) Postmeno-pause (N = 54) Premeno-pause (N = 149) Postmeno-pause (N = 113) Premeno-pause (N = 229) Postmeno-pause (N = 167)
n % n % n % n % n % n %
SBP* (mmHg) 6 4.5 8 6.0 13 5.0 29 11.1 19 4.8 37 9.3
DBP* (mmHg) 8 6.0 16 11.9 20 7.6 29 11.1 28 7.1 45 11.4
HDL* (mg/dl) 48 35.8 34 25.4 104 39.7 78 29.9 152 38.4 112 28.3
TG* (mg/dl) 56 41.8 46 34.3 116 44.3 100 38.3 172 43.4 146 36.9

Prevalence of the dyslipidemia risk factors and hypertension according to treatment exposure(1, 2, 3, 4)

Variables Cut-off points Newly diagnosed (n = 134) Recently – diagnosed (n = 262) Whole sample (n = 396)
Non-chemo (n = 86) Chemo (n = 176) Total (n = 262)
n % n % n % n % n %
SBP (mmHg) > 130 14 10.4a 8 9.3a 34 19.3b 42 16.0b 56 14.1
DBP (mmHg) > 85 24 17.9a 11 12.8a 38 21.6a 49 18.7a 73 18.4
Overt hypertension* 31 23.1 10 11.6 49 27.8 59 22.5 90 22.7
HDL-C (mg/dl) < 50 82 61.2a 70 81.4b 112 63.6a 182 69.5b 264 66.7
TG (mg/dl) > 150 102 76.1a 73 84.9b 143 81.2b 216 82.4b 318 80.3
TC (mg/dl) > 200 90 67.2a 75 87.2b 137 77.8b 212 80.9b 302 76.3
Overt dyslipidemia* 7 5.2 2 2.3 10 5.7 12 4.6 19 4.8

Dyslipidemia and hypertension characteristic in pre and postmenopause women according to treatment exposure(1, 2, 3, 4, 5)

Metabolic risks Newly-diagnosed (N = 134) Recently-diagnosed (N = 262) Whole sample (N = 396)
Premeno-pause (N = 80) Postmeno-pause (N = 54) Premeno-pause (N = 149) Postmeno-pause (N = 113) Premeno-pause (N = 229) Postmeno-pause (N = 167)
Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM
SBP*(mmHg) 117.1 1.5 121.1 1.7a 118.5 0.9 136.2 1.2b 118.0 0.8 129.3 1.0
DBP(mmHg) 76.6 1.4 80.9 1.1 78.3 0.6 80.2 1.0 78.0 0.6 80.0 0.7
HDL-C(mg/dl) 47.9 0.9 47.7 1.6 44.8 0.8 46.7 0.9 46.0 0.6 47.0 0.8
TG* (mg/dl) 182.5 6.9 215.3 9.6 201.7 6.1 223.5 7.4 195.0 4.7 221.0 5.9

Dyslipidaemia and hypertension characteristics according to treatment exposure(1, 2, 3)

Character Newly-diagnosed (n = 134) Recently – diagnosed (n=262) Whole sample (n = 396)
Non-chemo (n = 86) Chemo (n = 176) Total (n = 262)
Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM
SBP (mmHg) 119.1 1.1a 119.5 1.2a 123.0 0.9b 121.9 0.8a 120.9 0.6
DBP (mmHg) 78.4 1.0a 78.0 0.8a 79.6 0.7a 79.1 0.5a 78.8 0.5
HDL-C(mg/dl) 47.8 0.8a 42.9 1.0b 47.6 0.7a 45.6 0.6b 46.4 0.5
LDL-C (mg/dl) 126.9 9.0a 141.0 3.4a 128.8 2.8a 132.8 2.2a 130.8 3.4
TG (mg/dl) 195.7 5.8a 221.8 8.9b 205.9 5.6b 211.1 4.7b 205.9 3.7

Age-controlled partial correlation coefficients of dyslipidemia risk factors and hypertension with obesity indices and selected biomarkers in the study sample(1–2)

Metabolic risks BMI WC WHpR WHtR leptin HOMA C-peptide
SBR(mmHg) 0.04 0.08 0.12 0.08 0.10 0.14** 0.03
DBR (mmHg) 0.01 0.17*** 0.15** 0.13* 0.08 0.10* −0.02
HDL-C(mg/dl) −0.11* −0.11* −0.09 −0.13** −0.02 0.02 0.03
TG (mg/dl) 0.05 0.16*** 0.08 0.15** −0.11* 0.03 0.02
eISSN:
1792-362X
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology
Journal RSS Feed